BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GS101 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GS101\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07386743-1376@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:GS101: Phase 3 readout est. (NCT07386743)
DESCRIPTION:GS101\, phase 3\, Atopic Dermatitis.\nStudy: A Phase III Study 
 of GS101 Injection to Dupixent®\nEstimated primary completion: April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/gs101#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07386743
URL:https://assetmemo.bio/drug/gs101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
